Citations

Clear

6273 citation(s) found for "To, Andrew".

Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
Chang, Eileen , Keyhanian, Kiandokht, Huynh, Katie , Bhatti, M. Tariq , Chen, John J. , Costello, Fiona , Lott, Lindsey B. De , Egan, Robert A. , Fraser, Clare L, Freitag, Suzanne K. , Guidon, Amanda C. , Johnson, Douglas B. , Kombo, Ninani , Kramer, Michal , Lobo-Chan, Anne-Marie, Mantopoulos, Dimosthenis , Papaliodis, George N. , Pimkina, Julia, Rubin, Krista M., Sen, H. Nida, Shariff, Afreen , Subramanian, Prem S. , Tsui, Edmund , Yoon, Michael K. , McDunn, Jon, Rine, Johnathan, Reynolds, Kerry L. , Chwalisz, Bart K. , Levy, Michael , Huynh, Katie , Pless, Misha, Levy, Michael , Chen, John J , De Lott, Lindsey B , Liu, Renee , Berkenstock, Meghan , Chodosh, James , Dalvin, Lauren A. , Dinkin, Marc , Fraser, Clare L, Gangaputra, Sapna , Gordon, Lynn K. , Lee, Andrew G. , Levy, Michael, Lobo-Chan, Ann-Marie , Pless, Misha L , Sen, H. Nida , McDunn, Jon , Sobrin, Lucia

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 8, 2025 | Volume: 13 | Issue: 4 | Pages: e011049

10.1136/jitc-2024-011049 | PMID 40199607 Get It

Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in translational research. The objective of this study was to develop consensus guidance for an approach to Eye-irAEs. Four ophthalmic physicians (uveitis specialists and neuro-ophthalmologists) drafted Eye-irAE consensus guidance and definitions, which were reviewed by the multidisciplinary Eye-irAE definition panel. The panel was divided into Group A (Neuro-ophthalmology/Orbital Disease) and Group B (Uveitis/Ocular Surface Disease). A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. For each disorder, five diagnostic components were evaluated: symptoms, examination findings, laboratory studies/imaging findings, diagnostic criteria, and treatment. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free-text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND Corporation/ University of California Los Angeles Health Services Utilization Study (RAND/UCLA) Appropriateness Method with prespecified definitions. 29 panelists from 25 academic medical centers voted on 114 rating scales (66 neuro-ophthalmic/orbital disease components, 48 uveitis/ocular surface disease components); of these, 86.3% (57/66) in Group A and 89.6% (43/48) in Group B reached first-round consensus. After revisions, all items except 6.1% (4/66) in Group A and 1.6% (1/60) in Group B received second-round consensus. Consensus definitions were achieved for 10/11 neuro-ophthalmic/orbital disorders: optic neuritis, inflammatory optic disc edema, arteritic ischemic optic neuropathy, optic perineuritis, orbital inflammation, thyroid eye disease-like orbital inflammation, cavernous sinus syndrome, oculomotor mononeuritis, trochlear mononeuritis, and abducens mononeuritis. Consensus definitions were achieved for 9/10 uveitis/ocular surface disorders: anterior uveitis, intermediate uveitis, posterior uveitis, panuveitis, Vogt-Koyanagi-Harada-like syndrome, sarcoidosis-like syndrome, acute macular neuroretinopathy, dry eye disease, and scleritis. These disease definitions establish a standardized classification for Eye-irAE, highlighting differences between irAEs and other inflammatory disorders. Importantly, diagnostic certainty does not always align directly with the need to treat as an Eye-irAE. Given the consensus from this representative panel group, it is anticipated the definitions will be used broadly across clinical and research settings.
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
Dima, Danai , Afrough, Aimaz , Goel, Utkarsh , Grajales‐Cruz, Ariel , Khouri, Jack , Julian, Kelley , Banerjee, Rahul , Razzo, Beatrice M. , Ferreri, Christopher J. , Martinez, Mariola Alejandra Vazquez, Davis, James A. , Sannareddy, Aishwarya , Raza, Shahzad , Portuguese, Andrew J. , Gaballa, Mahmoud , Rana, Masooma , DeJarnette, Shaun, Gonzalez, Rebecca , Mikkilineni, Lekha , Hosoya, Hitomi , Ouchveridze, Evguenia, Shune, Leyla , Lin, Yi , Sborov, Douglas W. , Anderson, Larry D. , Cowan, Andrew J., Patel, Krina K. , Voorhees, Peter M. , Sidana, Surbhi , Hansen, Doris K., Susanibar-Adaniya, Sandra P. , Grajales-Cruz, Ariel F , Banerjee, Rahul , Vazquez-Martinez, Mariola A , Davis, James A , Portuguese, Andrew J , Rana, Masooma S , Lieberman-Cribbin, Alex , Chen, Anna , Herr, Megan M. , Anwer, Faiz , Sborov, Douglas W , Garfall, Alfred L , Lee, Hans C , Anderson, Larry D , Patel, Krina , Voorhees, Peter , Sidana, Surbhi , Dima, Danai , Raza, Shahzad , Hosoya, Hitomi , Julian, Kelley L , Susanibar-Adaniya, Sandra P , Pasvolsky, Oren , Vazquez‐Martinez, Mariola , Puglianini, Omar Castañeda , Ouchveridze, Evguenia, Kaur, Gurbakhash , Rossi, Adriana , Anwer, Faiz , Richard, Shambavi , Baz, Rachid , Garfall, Alfred L. , Lee, Hans C. , Hansen, Doris K. , Atrash, Shebli

Mayo Clinic

Blood Advances | April 8, 2025 | Volume: 9 | Issue: 14 | Pages: 3408-3417

10.1182/bloodadvances.2025016059 | PMID 40198766 Get It

Abstract Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) <40 mL/min. CrCl <30 mL/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade ≥3: 1.2% vs 1%) and immune effector cell–associated neurotoxicity syndrome (16% vs 13%; grade ≥3: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade ≥3 anemia and grade ≥3 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI.
The Digital Narrative: Chronic Pain Self-Management Insights from Reddit in Systemic Lupus Erythematosus
Park, Tricia , Le, Nathan , Irani, Anushka, Irani, Anushka , Irani, Anushka , Bozkurt, Selen , Walker, Andrew , Sarker, Abeed , Falasinnu, Titilola

Mayo Clinic

Studies in Health Technology and Informatics | April 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3233/shti250137 | PMID 40200534 Get It

Chronic pain is a pervasive and complex symptom experienced by patients with Systemic Lupus Erythematosus (SLE), often impacting their quality of life. Traditional data sources, such as clinical records and surveys, provide valuable insights but may not fully capture the breadth of patient experiences and self-management strategies. This study leverages Reddit discussions as a real-world data source to explore chronic pain patterns, management approaches, and unmet needs among individuals with SLE. Utilizing natural language processing (NLP), we analyzed over 30,000 posts from r/Lupus and r/LupusSupport subreddits to identify key themes, trends, and alternative therapies discussed by users. This approach highlights the potential of social media as a complementary resource for understanding chronic pain and guiding patient-centered care interventions.
Cytokine, Chemokine, and Neurofilament Light Chain Signatures in Anti-LGI-1 Encephalitis (S7.002)
Mangioris, Georgios , Yang, Binxia , Day, Gregory S. , Lopez, Alfonso, McKeon, Andrew, Tolédano, Michel B. , Vodopivec, Ivana, Ζεκερίδου, Αναστασία , Day, Gregory S , Aboseif, Albert , Yang, Binxia , Segal‬‏, Yahel , Dubey, Divyanshu , Flanagan, Eoin P. , Irani, Sarosh R. , Britton, Jeffrey W. , McKeon, Andrew , Toledano, Michel, Pittock, Sean J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211378 Get It

Recurrence of a Chondroid Tenosynovial Giant Cell Tumor in the Temporomandibular Joint (P9-6.013)
Khawaja, Anusha, Lanzino, Guiseppe, Torres‐Mora, Jorge , Folpe, Andrew, Khawaja, Anusha, Johnson, Derek R. , Sener, Uğur

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000208461 Get It

Long-term Outcomes in Patients with GAD65-IgG-positive Stiff Person Syndrome Spectrum Disorder (P2-8.008)
Mangioris, Georgios , McKeon, Andrew, Bower, James H., Dubey, Divyanshu , Ζεκερίδου, Αναστασία , McKeon, Andrew , Dubey, Divyanshu , Flanagan, Eoin P. , Pittock, Sean J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211915 Get It

Immature Ovarian Teratomas in Anti-NMDA Receptor Encephalitis: A Case Series (P3-8.015)
Nathoo, Nabeela , Simone, Kristen, Buletko, Andrew , Pin, Sophia , Nathoo, Nabeela , Aboseif, Albert , McCombe, Jennifer A.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211091 Get It

‘Amphiphysin-like’ IgGs Targeting Novel Synaptic Vesicle Trafficking Autoantigens (P1-8.002)
Gilligan, Michael , Mills, John R. , Vargas, Paulina, Lesnick, Connie , Basal, Eati, LaFrance‐Corey, Reghann G., Dasari, Surendra , Ζεκερίδου, Αναστασία , Pittock, Sean J, McKeon, Andrew, Vargas, Paulina, Paramasivan, Naveen Kumar , Pittock, Sean J. , Dubey, Divyanshu , McKeon, Andrew

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211028 Get It